Get the Stockscreener App
4.00
1.01%
0.04
Engene Holdings Inc stock is traded at $4.00, with a volume of 14,114.
It is up +1.01% in the last 24 hours and down -22.03% over the past month.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
See More
Previous Close:
$3.96
Open:
$3.9
24h Volume:
14,114
Relative Volume:
0.17
Market Cap:
$203.91M
Revenue:
-
Net Income/Loss:
$-103.21M
P/E Ratio:
-0.8695
EPS:
-4.6001
Net Cash Flow:
$-26.70M
1W Performance:
+0.00%
1M Performance:
-22.03%
6M Performance:
-56.99%
1Y Performance:
-74.59%
1-Day Range:
$3.81
$4.05
1-Week Range:
$3.77
$4.19
52-Week Range:
$3.50
$16.62
Engene Holdings Inc Stock (ENGN) Company Profile
Name
Engene Holdings Inc
Sector
Industry
Phone
(514) 332-4888
Address
4868 RUE LEVY, SUITE 220, SAINT-LAURENT
Compare ENGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENGN
Engene Holdings Inc
|
4.00 | 203.91M | 0 | -103.21M | -26.70M | -4.6001 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Engene Holdings Inc Stock (ENGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-18-25 | Initiated | Piper Sandler | Overweight |
| Feb-14-25 | Downgrade | UBS | Buy → Neutral |
| Dec-23-24 | Initiated | H.C. Wainwright | Buy |
| Nov-27-24 | Initiated | Raymond James | Outperform |
| Nov-18-24 | Initiated | JMP Securities | Mkt Outperform |
| Aug-28-24 | Initiated | Oppenheimer | Outperform |
| Apr-22-24 | Initiated | Wells Fargo | Overweight |
| Apr-15-24 | Initiated | Guggenheim | Buy |
| Mar-28-24 | Initiated | UBS | Buy |
| Mar-08-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | Leerink Partners | Outperform |
View All
Engene Holdings Inc Stock (ENGN) Latest News
enGene (NASDAQ:ENGN) & Innate Pharma (OTCMKTS:IPHYF) Head-To-Head Survey - Defense World
Trend Tracker for (ENGN) - news.stocktradersdaily.com
Engene Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
enGene Expands Team with New Hires, Grants 144,650 Shares in Stock Options - Stock Titan
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
Strategic Oncology Updates Coming: enGene CEO Headlines Stifel Healthcare Forum - Stock Titan
How the (ENGN) price action is used to our Advantage - news.stocktradersdaily.com
Promising Trajectory and Strong Financial Position Justify Buy Rating for enGene Holdings - TipRanks
enGene Holdings Insider Ups Holding During Year - Yahoo Finance
enGene Holdings Inc.'s (NASDAQ:ENGN) market cap dropped US$33m last week; individual investors who hold 38% were hit as were institutions - Simply Wall St
enGene’s (ENGN) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
enGene (NASDAQ:ENGN) Price Target Lowered to $34.00 at Morgan Stanley - Defense World
Engene stock holds Buy rating, $25 target from H.C. Wainwright - Investing.com
Engene stock holds Buy rating, $25 target from H.C. Wainwright By Investing.com - Investing.com South Africa
enGene Reports First Quarter 2025 Financial Results and Provides Business Update - BioSpace
enGene Holdings Inc. SEC 10-Q Report - TradingView
enGene Reports Q1 Results: Strong Cash Position Funds Global Trial Expansion - StockTitan
Trading (ENGN) With Integrated Risk Controls - Stock Traders Daily
enGene to Participate in the Leerink Partners Global Healthcare Conference - Business Wire
What Will enGene Reveal? CEO's Upcoming Fireside Chat at Major Healthcare Conference - Stock Titan
Lumira Ventures Portfolio Company enGene (Nasdaq:ENGN) Debuts as Publicly Traded Genetic Medicines Company - ACCESS Newswire
enGene Holdings Inc.: Unknown Company Which Looks Like A Catch (NASDAQ:ENGN) - Seeking Alpha
Financial Contrast: enGene (NASDAQ:ENGN) versus iTeos Therapeutics (NASDAQ:ITOS) - Defense World
(ENGN) On The My Stocks Page - Stock Traders Daily
Vontobel Holding Ltd. Makes New $69,000 Investment in enGene Holdings Inc. (NASDAQ:ENGN) - Defense World
enGene Holdings Inc. (NASDAQ:ENGN) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
enGene (NASDAQ:ENGN) Coverage Initiated at Piper Sandler - Armenian Reporter
enGene Holdings GAAP EPS of -$0.38 - MSN
New Strong Buy Stocks for February 19th - Zacks Investment Research
enGene (NASDAQ:ENGN) Now Covered by Piper Sandler - Defense World
Best Momentum Stocks to Buy for February 19th - Nasdaq
enGene Holdings Inc. (NASDAQ:ENGN) Given Average Rating of “Buy” by Brokerages - Defense World
Piper Sandler sets $26 target on Engene shares with Overweight rating - Investing.com Australia
This aTyr Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Buy Rating for enGene Holdings: Strategic Positioning and Growth Potential in NMIBC Market - TipRanks
Piper Sandler Initiates Coverage on enGene Holdings With Overweight Rating, $26 Price Target - Marketscreener.com
Piper Sandler sets $26 target on Engene shares with Overweight rating By Investing.com - Investing.com South Africa
Analyzing Ratios: enGene Holdings Inc (ENGN)’s Financial Story Unveiled - The Dwinnex
enGene (NASDAQ:ENGN) Stock Rating Lowered by UBS Group - Defense World
enGene (NASDAQ:ENGN) Downgraded to Neutral Rating by UBS Group - MarketBeat
Sector Update: Health Care -February 14, 2025 at 03:41 pm EST - Marketscreener.com
EnGene Holdings Shares Fall After UBS Downgrade -February 14, 2025 at 02:55 pm EST - Marketscreener.com
UBS Downgrades enGene Holdings to Neutral From Buy, Cuts Price Target to $7 From $34 - Marketscreener.com
enGene downgraded to Neutral from Buy at UBS - TipRanks
(ENGN) Pivots Trading Plans and Risk Controls - Stock Traders Daily
enGene Holdings Inc (ENGN) vs. Its Peers: A Comparison - The News Heater
enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Business Wire
Where are the Opportunities in (ENGN) - Stock Traders Daily
ENGNenGene Holdings Inc. Latest Stock News & Market Updates - StockTitan
enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC) - Business Wire
FY2026 EPS Estimates for enGene Boosted by Leerink Partnrs - Defense World
Engene Holdings Inc Stock (ENGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):